Quantbot Technologies LP Acquires New Position in Doximity, Inc. (NASDAQ:DOCS)

Quantbot Technologies LP acquired a new position in Doximity, Inc. (NASDAQ:DOCS) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 75,327 shares of the company’s stock, valued at approximately $4,022,000.

A number of other hedge funds have also bought and sold shares of DOCS. Global Retirement Partners LLC boosted its stake in Doximity by 468.1% during the fourth quarter. Global Retirement Partners LLC now owns 534 shares of the company’s stock valued at $29,000 after buying an additional 440 shares during the period. UMB Bank n.a. raised its stake in Doximity by 69.1% in the fourth quarter. UMB Bank n.a. now owns 575 shares of the company’s stock valued at $31,000 after purchasing an additional 235 shares in the last quarter. Farther Finance Advisors LLC lifted its position in Doximity by 324.2% during the third quarter. Farther Finance Advisors LLC now owns 789 shares of the company’s stock valued at $34,000 after purchasing an additional 603 shares during the last quarter. Larson Financial Group LLC increased its holdings in shares of Doximity by 49.4% in the 4th quarter. Larson Financial Group LLC now owns 756 shares of the company’s stock worth $40,000 after buying an additional 250 shares during the last quarter. Finally, Morse Asset Management Inc purchased a new stake in shares of Doximity during the 3rd quarter valued at $46,000. 87.19% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Doximity

In other news, Director Timothy S. Cabral sold 20,000 shares of the company’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $57.62, for a total value of $1,152,400.00. Following the transaction, the director now directly owns 6,360 shares in the company, valued at approximately $366,463.20. This represents a 75.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 37.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Stephens assumed coverage on Doximity in a research note on Friday, December 20th. They issued an “equal weight” rating and a $55.00 target price on the stock. Leerink Partnrs raised Doximity from a “hold” rating to a “strong-buy” rating in a research note on Friday, February 7th. Wells Fargo & Company reissued an “equal weight” rating on shares of Doximity in a research note on Friday, February 7th. The Goldman Sachs Group upped their price objective on shares of Doximity from $58.00 to $80.00 and gave the company a “neutral” rating in a research note on Monday, February 10th. Finally, Raymond James reissued an “outperform” rating and issued a $83.00 price target (up from $65.00) on shares of Doximity in a research note on Friday, February 7th. Eleven research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $64.22.

Doximity Stock Performance

Shares of NASDAQ:DOCS opened at $63.33 on Friday. The firm has a market cap of $11.82 billion, a price-to-earnings ratio of 63.33, a P/E/G ratio of 4.10 and a beta of 1.34. Doximity, Inc. has a fifty-two week low of $22.96 and a fifty-two week high of $85.21. The firm has a fifty day moving average price of $63.63 and a 200 day moving average price of $52.49.

Doximity Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.